Actinium Pharmaceuticals, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a total revenue of $90,000 for the nine months ended September 30, 2025, unchanged from the same period in 2024. The company did not generate any commercial revenue during the quarter. Operating expenses for the third quarter decreased to $5.8 million from $12.6 million in the prior year, primarily due to reduced research and development costs, which fell from $9.8 million to $4.2 million. The net loss for the third quarter was $5.1 million, a significant improvement compared to a net loss of $11.6 million in the same quarter of 2024.
For the nine-month period, Actinium's total operating expenses were $29.9 million, down from $34.6 million in the previous year. The decrease was attributed to lower research and development expenses, which dropped from $25.2 million to $16.8 million, and a rise in general and administrative expenses from $9.4 million to $13.1 million, largely due to increased stock-based compensation expenses following the cancellation of stock options. The net loss for the nine months ended September 30, 2025, was $27.9 million, compared to $31.6 million for the same period in 2024.
Actinium's cash and cash equivalents decreased to $53.4 million as of September 30, 2025, down from $72.9 million at the end of 2024. The company reported cash used in operating activities of $19.3 million for the nine months ended September 30, 2025, a decrease from $27.3 million in the prior year. The company did not engage in any sales of common stock during the nine months ended September 30, 2025, contrasting with the previous year when it raised approximately $29.3 million from stock sales.
Strategically, Actinium is focused on advancing its pipeline of targeted radiotherapies, including its lead program, ATNM-400, which is designed to treat various cancers. The company is also working on Iomab-ACT, a targeted conditioning agent for cell and gene therapies. Actinium has been actively seeking partnerships to enhance its development efforts, particularly for Iomab-B, which is aimed at improving outcomes for patients undergoing bone marrow transplants. The company has approximately 250 issued and pending patents worldwide, supporting its innovative pipeline.
Looking ahead, Actinium anticipates that its existing resources will be sufficient to fund operations for more than 12 months following the report date. The company is also preparing for potential clinical trials and regulatory submissions, while navigating challenges posed by recent geopolitical events and the impact of the U.S. federal government shutdown on its operations.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies using alpha-emitting isotopes to treat advanced cancers, including myeloid malignancies, solid tumors, and conditioning for cell and gene therapies. Its clinical-stage pipeline features Actimab-A for AML and MDS, Iomab-ACT for conditioning prior to cellular therapies, and ATNM-400 for prostate cancer. The company integrates radioisotope production, drug manufacturing, and clinical development, leveraging proprietary Ac-225 technology and a broad patent portfolio.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.